Polyamine patterns in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy

2010 ◽  
Vol 411 (19-20) ◽  
pp. 1532-1535 ◽  
Author(s):  
Man-Jeong Paik ◽  
Young-Hwan Ahn ◽  
Phil Hyu Lee ◽  
Hyunseung Kang ◽  
Chan Bae Park ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Multiple System Atrophy

Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease

2004 ◽  
Vol 19 (5) ◽  
pp. 571-579 ◽  
Author(s):  
W. Farid Abdo ◽  
Dani�lle De Jong ◽  
Jan C.M. Hendriks ◽  
Martin W.I.M. Horstink ◽  
Berry P.H. Kremer ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Multiple System Atrophy ◽  
Cerebrospinal Fluid Analysis ◽  
Fluid Analysis

Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy

2012 ◽  
Vol 27 (7) ◽  
pp. 851-857 ◽  
Author(s):  
Noriko Ishigami ◽  
Takahiko Tokuda ◽  
Masaya Ikegawa ◽  
Mika Komori ◽  
Takashi Kasai ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Multiple System Atrophy

scholarly journals Cerebrospinal Fluid Levels of Chromogranin A in Parkinson’s Disease and Multiple System Atrophy

2021 ◽  
Vol 11 (2) ◽  
pp. 141
Author(s):  
Michaela Kaiserova ◽  
Monika Chudackova ◽  
Katerina Mensikova ◽  
Miroslav Vastik ◽  
Sandra Kurcova ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Multiple System Atrophy ◽  
Chromogranin A ◽  
Disease Duration ◽  
Statistical Significance ◽  
Control Group ◽  
Dose Equivalent ◽  
Levodopa Dose

Background: Chromogranin A (CgA) and other peptides from the chromogranin–secretogranin family have been recently studied as potential biomarkers of various neurodegenerative diseases, including Parkinson’s disease (PD). Methods: We measured CgA in the cerebrospinal fluid (CSF) of 119 PD patients, 18 multiple system atrophy (MSA) patients, and 31 age-matched controls. We also correlated the values with disease duration and levodopa dose equivalent. Results: In the PD patients, CSF CgA tended to be lower than the control group (median 124.5 vs. 185.2 µg/L; p = 0.057); however, the results did not reach statistical significance. CSF CgA levels in MSA were significantly lower compared to the control group (median 104.4 vs. 185.2; p = 0.014). There was no significant difference in CSF CgA between PD and MSA patients (p = 0.372). There was no association between CSF CgA and disease duration or levodopa dose equivalent in PD or in MSA. Conclusions: We observed a tendency toward lower CSF CgA levels in both PD and MSA compared to the control group; however, the difference reached statistical significance only in MSA. Based on these results, CgA may have potential as a biomarker in PD and MSA, but further studies on larger numbers of patients are needed to draw conclusions.

Sign in / Sign up

Export Citation Format

Share Document